Skip to content
value.today

Ascus Bioscience, Inc.

Formerly Newco Fungi, Inc.

Total raised
$29 M
4 rounds on record
Latest round
$5 M
May 2019
First round on record
Apr 2016
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ascus Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2019$5 MNo. 4$2 to $10 million

Ascus Bioscience, Inc.: Raise no. 4, May 2019

Investors in this round

10 investors had bought by the notice of Jun 13, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mallory Embree · Executive Officer, Director
  • Michael Seely · Executive Officer, Director
  • Erik Torgerson · Director
  • Jim Kim · Director
  • Peter Innes · Director
  • Thad Simons · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Consists of Convertible Promissory Notes convertible into shares of Preferred Stock of the Issuer.”

Signed by Michael Seely, President and CEO. Source: SEC Form D, newest notice filed Jun 13, 2019. Read the notice at the SEC.

debt, optionsSEC
Aug 2018$6 MNo. 3$2 to $10 million

Ascus Bioscience, Inc.: Raise no. 3, Aug 2018

Investors in this round

6 investors had bought by the notice of Sep 5, 2018: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $8 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mallory Embree · Executive Officer, Director
  • Michael Seely · Executive Officer, Director
  • Erik Torgerson · Director
  • Jim Kim · Director
  • Peter Innes · Director
  • Thad Simons · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Consists of Convertible Promissory Notes convertible into shares of Preferred Stock of the Issuer.”

Signed by Michael Seely, President and CEO. Source: SEC Form D, newest notice filed Sep 5, 2018. Read the notice at the SEC.

debt, optionsSEC
Jun 2017$5 MNo. 2$2 to $10 million

Ascus Bioscience, Inc.: Raise no. 2, Jun 2017

Investors in this round

9 investors had bought by the notice of Jul 11, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $7 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mallory Embree · Executive Officer, Director
  • Michael Seely · Executive Officer, Director
  • Erik Torgerson · Director
  • Jim Kim · Director
  • Peter Innes · Director
  • Thad Simons · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Consists of Convertible Promissory Notes convertible into shares of Preferred Stock of the Issuer.”

Signed by Michael Seely, President and CEO. Source: SEC Form D, newest notice filed Jul 11, 2017. Read the notice at the SEC.

debt, optionsSEC
Apr 2016$13 MNo. 1$10 to $50 million

Ascus Bioscience, Inc.: Raise no. 1, Apr 2016

Investors in this round

9 investors had bought by the notice of Apr 26, 2016: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $14 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Seely · Executive Officer, Director
  • Jim Kim · Director
  • Mallory Embree · Director
  • Peter Innes · Director
  • Thad Simons · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Seely, President. Source: SEC Form D, newest notice filed Apr 26, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ascus Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2019).

    SEC Form D · Jun 2019

  • The industry group it chose in its notices: Other.

    SEC Form D · Jun 2019

That is all the official record says: Ascus Bioscience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Ascus Bioscience, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ascus Bioscience, Inc.
NameRoleNamed in
Mallory EmbreeExecutive officerJun 2019
Michael SeelyExecutive officerJun 2019
Erik TorgersonDirectorJun 2019
Jim KimDirectorJun 2019
Mallory EmbreeDirectorJun 2019
Michael SeelyDirectorJun 2019
Peter InnesDirectorJun 2019
Thad SimonsDirectorJun 2019